In the wake of the Supreme Court’s ruling that unmodified genes are not patentable, several companies say they will or already have begun selling diagnostic tests that will compete directly against Myriad Genetics Inc.’s BRACAnalysis test for predisposition to hereditary breast and ovarian cancer.
The court unanimously overturned Myriad’s patents on the BRCA1 and BRCA2 genes that underlie the test as part of its decision earlier this month in Association of Molecular Pathology v. Myriad